Vitamin D and immune response: Implications for prostate cancer in African Americans

Frontiers in Immunology

Volumn 7, Issue FEB, 2016, Pages

  Batai, Ken ^a   Murphy, Adam B ^b,c   Nonn, Larisa ^d   Kittles, Rick A ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

African Americans; Health disparities; Inflammation; Prostate cancer; Vitamin D

Indexed keywords

CALCITRIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN SYNTHASE; PROSTATE SPECIFIC ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

AFRICAN AMERICAN; ANTIINFLAMMATORY ACTIVITY; CANCER GRADING; CANCER RISK; CLINICAL TRIAL (TOPIC); GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MORTALITY RATE; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR IMMUNITY; VITAMIN D DEFICIENCY;

EID: 84962564410     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00053     Document Type: Short Survey

References (145)

1. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate (2011) 71:985-97. doi: 10.1002/pros.21314.
2. Major J, Norman Oliver M, Doubeni C, Hollenbeck A, Graubard B, Sinha R. Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. Cancer Causes Control (2012) 23:1185-91. doi:10.1007/s10552-012-9988-8.
3. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer (2012) 131:1187-96. doi:10.1002/ijc.27327.
4. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst (2012) 104:690-9. doi:10.1093/jnci/djs189.
5. Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CMP, Nadler RB, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res (2014) 20:2289-99. doi:10.1158/1078-0432.ccr-13-3085.
6. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst (2008) 100:796-804. doi:10.1093/jnci/djn152.
7. Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjønneland A, et al. Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European prospective investigation into cancer and nutrition (EPIC). Am J Epidemiol (2009) 169:1223-32. doi:10.1093/aje/kwp022.
8. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, Virtamo J, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev (2011) 20:1850-60. doi:10.1158/1055-9965.epi-11-0403.
9. Park S-Y, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN. Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer (2010) 46:932-6. doi:10.1016/j.ejca.2009.12.030.
10. Egan K, Signorello L, Munro H, Hargreaves M, Hollis B, Blot W. Vitamin D insufficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States). Cancer Causes Control (2008) 19:527-35. doi:10.1007/s10552-008-9115-z.
11. Jacobs ET, Alberts DS, Foote JA, Green SB, Hollis BW, Yu Z, et al. Vitamin D insufficiency in southern Arizona. Am J Clin Nutr (2008) 87:608-13.
12. Levis S, Gomez A, Jimenez C, Veras L, Ma F, Lai S, et al. Vitamin D deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab (2005) 90:1557-62. doi:10.1210/jc.2004-0746.
13. Grant WB, Peiris AN. Possible role of serum 25-hydroxyvitamin D in Black-White health disparities in the United States. J Am Med Dir Assoc (2010) 11:617-28. doi:10.1016/j.jamda.2010.03.013.
14. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol (2013) 136:233-7. doi:10.1016/j.jsbmb.2012.11.012.
15. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer (2007) 7:684-700. doi:10.1038/nrc2196.
16. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer (2014) 14:342-57. doi:10.1038/nrc3691.
17. Krishnan AV, Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer (2010) 17:R19-38. doi:10.1677/erc-09-0139.
18. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol (2004) 92:131-41. doi:10.1016/j.jsbmb.2004.07.003.
19. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate (2004) 59:243-51. doi:10.1002/pros.20006.
20. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 7:256-69. doi:10.1038/nrc2090.
21. Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev (2013) 22:891-7. doi:10.1158/1055-9965.epi-12-1238.
22. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 68:927-36. doi:10.1158/0008-5472.can-07-2608.
23. Kinseth MA, Jia Z, Rahmatpanah F, Sawyers A, Sutton M, Wang-Rodriguez J, et al. Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int J Cancer (2014) 134:81-91. doi:10.1002/ijc.28326.
24. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014) 64:9-29. doi:10.3322/caac.21208.
25. Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol (1998) 160:437-42. doi:10.1016/S0022-5347(01)62919-7.
26. Berger AD, Satagopan J, Lee P, Taneja SS, Osman I. Differences in clinicopathologic features of prostate cancer between black and white patients treated in the 1990s and 2000s. Urology (2006) 67:120-4. doi:10.1016/j.urology.2005.08.005.
27. Bigler SA, Pound CR, Zhou X. A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer (2011) 2011:239460. doi:10.1155/2011/239460.
28. Cullen J, Brassell SA, Chen Y, Porter C, L'esperance J, Brand T, et al. Racial/ethnic patterns in prostate cancer outcomes in an active surveillance cohort. Prostate Cancer (2011) 2011:234519. doi:10.1155/2011/234519.
29. Ha Y-S, Salmasi A, Karellas M, Singer EA, Kim JH, Han M, et al. Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology (2013) 81:831-6. doi:10.1016/j.urology.2012.12.046.
30. Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 31:2991-7. doi:10.1200/JCO.2012.47.0302.
31. Farrell J, Petrovics G, McLeod D, Srivastava S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci (2013) 14:15510-31. doi:10.3390/ijms140815510.
32. Martin DN, Starks AM, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol (2013) 25:235-41. doi:10.1097/CCO.0b013e32835eb5d1.
33. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in Black than in White American men, and influences racial progression and mortality disparity. J Urol (2010) 183:1792-7. doi:10.1016/j.juro.2010.01.015.
34. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. The role of vitamin D in cancer prevention. Am J Public Health (2006) 96:252-61. doi:10.2105/ajph.2004.045260.
35. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control (2005) 16:83-95. doi:10.1007/s10552-004-1661-4.
36. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One (2011) 6:e18625. doi:10.1371/journal.pone.0018625.
37. Li H, Stampfer MJ, Hollis JBW, Mucci LA, Gaziano JM, Hunter D, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med (2007) 4:e103. doi:10.1371/journal.pmed.0040103.
38. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer (2009) 100:450-4. doi:10.1038/sj.bjc.6604865.
39. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev (1996) 5:121-6.
40. Jacobs ET, Giuliano AR, Martínez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol (2004) 8(9-90):533-7. doi:10.1016/j.jsbmb.2004.03.063.
41. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control (2004) 15:255-65. doi:10.1023/B:CACO.0000024245.24880.8a.
42. Deschasaux M, Souberbielle J-C, Latino-Martel P, Sutton A, Charnaux N, Druesne-Pecollo N, et al. A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk. Br J Nutr (2016) 115:305-14. doi:10.1017/S0007114515004353.
43. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2014) 23:1494-504. doi:10.1158/1055-9965.epi-14-0115.
44. Chan J, Jaceldo-Siegl K, Fraser G. Determinants of serum 25 hydroxyvitamin D levels in a nationwide cohort of blacks and non-Hispanic whites. Cancer Causes Control (2010) 21:501-11. doi:10.1007/s10552-009-9481-1.
45. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr (2008) 88:1519-27. doi:10.3945/ajcn.2008.26182.
46. Batai K, Murphy A, Shah E, Ruden M, Newsome J, Agate S, et al. Common vitamin D pathway gene variants reveal contrasting effects on serum vitamin D levels in African Americans and European Americans. Hum Genet (2014) 133:1395-405. doi:10.1007/s00439-014-1472-y.
47. Murphy AB, Kelley B, Nyame YA, Martin IK, Smith DJ, Castaneda L, et al. Predictors of serum vitamin D levels in African American and European American men in Chicago. Am J Mens Health (2012) 6:420-6. doi:10.1177/1557988312437240.
48. Tseng M, Giri V, Bruner D, Giovannucci E. Prevalence and correlates of vitamin D status in African American men. BMC Public Health (2009) 9:191. doi:10.1186/1471-2458-9-191.
49. Shea MK, Houston DK, Tooze JA, Davis CC, Johnson MA, Hausman DB, et al. Correlates and prevalence of insufficient 25-hydroxyvitamin D status in Black and White older adults: the Health, Aging and Body Composition Study. J Am Geriatr Soc (2011) 59:1165-74. doi:10.1111/j.1532-5415.2011.03476.x.
50. Giovannucci E, Liu Y, Willett WC. Cancer incidence and mortality and vitamin D in black and white male health professionals. Cancer Epidemiol Biomarkers Prev (2006) 15:2467-72. doi:10.1158/1055-9965.epi-06-0357.
51. Holick MF. Vitamin D deficiency. N Engl J Med (2007) 357:266-81. doi:10.1056/NEJMra070553.
52. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev (1998) 7:391-5.
53. Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev (2000) 9:265-70.
54. Banks M, Holick MF. Molecular mechanism(s) involved in 25-hydroxyvitamin D's antiproliferative effects in CYP27B1-transfected LNCaP cells. Anticancer Res (2015) 35:3773-9.
55. Li H-X, Gao J-M, Liang J-Q, Xi J-M, Fu M, Wu Y-J. Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway. Clin Exp Pharmacol Physiol (2015) 42:711-7. doi:10.1111/1440-1681.12409.
56. Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J (2010) 16:1-9. doi:10.1097/PPO.0b013e3181c51ee6.
57. Giangreco AA, Dambal S, Wagner D, Van der Kwast T, Vieth R, Prins GS, et al. Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model. J Steroid Biochem Mol Biol (2015) 148:156-65. doi:10.1016/j.jsbmb.2014.10.004.
58. Krill D, DeFlavia P, Dhir R, Luo J, Becich MJ, Lehman E, et al. Expression patterns of vitamin D receptor in human prostate. J Cell Biochem (2001) 82:566-72. doi:10.1002/jcb.1185.
59. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol (2011) 29:2378-85. doi:10.1200/jco.2010.30.9880.
60. Strasner A, Karin M. Immune infiltration and prostate cancer. Front Oncol (2015) 5:128. doi:10.3389/fonc.2015.00128.
61. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med (2003) 349:366-81. doi:10.1056/NEJMra021562.
62. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology (2012) 60:199-215. doi:10.1111/j.1365-2559.2011.04033.x.
63. Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2014) 23:847-56. doi:10.1158/1055-9965.epi-13-1126.
64. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res (2015) 21:756-62. doi:10.1158/1078-0432.CCR-14-2235.
65. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer (2014) 120:190-6. doi:10.1002/cncr.28349.
66. Eastham JA, May RA, Whatley T, Crow A, Venable DD, Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst (1998) 90:756-60. doi:10.1093/jnci/90.10.756.
67. Reams RR, Agrawal D, Davis M, Yoder S, Odedina F, Kumar N, et al. Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect Agent Cancer (2009) 4:S3. doi:10.1186/1750-9378-4-S1-S3.
68. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer (2012) 19:R187-204. doi:10.1530/ERC-12-0085.
69. Hägglöf C, Bergh A. The stroma-a key regulator in prostate function and malignancy. Cancers (2012) 4:531-48. doi:10.3390/cancers4020531.
70. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis (2010) 31:455-61. doi:10.1093/carcin/bgp307.
71. Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, et al. Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2011) 20:923-33. doi:10.1158/1055-9965.EPI-10-0994.
72. Magalhães JF, Cortinhas AJ, Albuquerque CM, Baptista CS, Ribeiro R, Viegas C, et al. Interleukin-6 gene-174G>C and-636G>C promoter polymorphisms and prostate cancer risk. Mol Biol Rep (2013) 40:449-55. doi:10.1007/s11033-012-2079-9.
73. Tan D, Wu X, Hou MIN, Lee SOK, Lou WEI, Wang J, et al. Interleukin-6 polymorphism is associated with more aggressive prostete caner. J Urol (2005) 174:753-6. doi:10.1097/01.ju.0000168723.42824.40.
74. Zabaleta J, Lin H-Y, Sierra RA, Hall MC, Clark PE, Sartor OA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis (2008) 29:573-8. doi:10.1093/carcin/bgm277.
75. Batai K, Shah E, Murphy AB, Newsome J, Ruden M, Ahaghotu C, et al. Fine-mapping of IL16 gene and prostate cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev (2012) 21:2059-68. doi:10.1158/1055-9965.epi-12-0707.
76. Kidd L, Jones D, Rogers E, Kidd N, Beache S, Rudd J, et al. Chemokine ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study. Hered Cancer Clin Pract (2012) 10:16. doi:10.1186/1897-4287-10-16.
77. Jones D, Ragin C, Kidd N, Flores-Obando R, Jackson M, McFarlane-Anderson N, et al. The impact of genetic variants in inflammatory-related genes on prostate cancer risk among men of African Descent: a case control study. Hered Cancer Clin Pract (2013) 11:19. doi:10.1186/1897-4287-11-19.
78. Rogers EN, Jones DZ, Kidd NC, Yeyeodu S, Brock G, Ragin C, et al. Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent. Genes Immun (2013) 14:347-55. doi:10.1038/gene.2013.22.
79. Mason TE, Ricks-Santi L, Chen W, Apprey V, Joykutty J, Ahaghotu C, et al. Association of CD14 variant with prostate cancer in African American men. Prostate (2010) 70:262-9. doi:10.1002/pros.21060.
80. Van Dyke AL, Cote ML, Wenzlaff AS, Land S, Schwartz AG. Cytokine SNPs: comparison of allele frequencies by race and implications for future studies. Cytokine (2009) 46:236-44. doi:10.1016/j.cyto.2009.02.003.
81. Ness RB, Haggerty CL, Harger G, Ferrell R. Differential distribution of allelic variants in cytokine genes among African Americans and White Americans. Am J Epidemiol (2004) 160:1033-8. doi:10.1093/aje/kwh325.
82. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukinn-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol (1999) 161:182-7. doi:10.1016/S0022-5347(01)62092-5.
83. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer (2004) 90:2312-6. doi:10.1038/sj.bjc.6601814.
84. Tazaki E, Shimizu N, Tanaka R, Yoshizumi M, Kamma H, Imoto S, et al. Serum cytokine profiles in patients with prostate carcinoma. Exp Ther Med (2011) 2:887-91. doi:10.3892/etm.2011.286.
85. Coe CL, Love GD, Karasawa M, Kawakami N, Kitayama S, Markus HR, et al. Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. Brain Behav Immun (2011) 25:494-502. doi:10.1016/j.bbi.2010.11.013.
86. Beasley LE, Koster A, Newman AB, Javaid MK, Ferrucci L, Kritchevsky SB, et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (2009) 17:1062-9. doi:10.1038/oby.2008.627.
87. Wacker M, Holick M. Vitamin D-effects on skeletal and extraskeletal health and the need for supplementation. Nutrients (2013) 5:111-48. doi:10.3390/nu5010111.
88. Wöbke TK, Sorg BL, Steinhilber D. Vitamin D in inflammatory diseases. Front Physiol (2014) 5:244. doi:10.3389/fphys.2014.00244.
89. Barker T, Martins T, Hill H, Kjeldsberg C, Dixon B, Schneider E, et al. Circulating pro-inflammatory cytokines are elevated and peak power output correlates with 25-hydroxyvitamin D in vitamin D insufficient adults. Eur J Appl Physiol (2013) 113:1523-34. doi:10.1007/s00421-012-2582-7.
90. Bellia A, Garcovich C, D'Adamo M, Lombardo M, Tesauro M, Donadel G, et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med (2013) 8:33-40. doi:10.1007/s11739-011-0559-x.
91. Peterson C, Heffernan M. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (2008) 5:10. doi:10.1186/1476-9255-5-10.
92. Sun X, Cao Z-B, Zhang Y, Ishimi Y, Tabata I, Higuchi M. Association between serum 25-hydroxyvitamin D and inflammatory cytokines in healthy adults. Nutrients (2014) 6:221-30. doi:10.3390/nu6010221.
93. De Vita F, Lauretani F, Bauer J, Bautmans I, Shardell M, Cherubini A, et al. Relationship between vitamin D and inflammatory markers in older individuals. Age (2014) 36:1-13. doi:10.1007/s11357-014-9694-4.
94. Amer M, Qayyum R. Relation between serum 25-hydroxyvitamin D and C-reactive protein in asymptomatic adults (from the continuous National Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol (2012) 109:226-30. doi:10.1016/j.amjcard.2011.08.032.
95. Laird E, McNulty H, Ward M, Hoey L, McSorley E, Wallace JMW, et al. Vitamin D deficiency is associated with inflammation in older Irish adults. J Clin Endocrinol Metab (2014) 99:1807-15. doi:10.1210/jc.2013-3507.
96. Chen N, Wan Z, Han S-F, Li B-Y, Zhang Z-L, Qin L-Q. Effect of vitamin D supplementation on the level of circulating high-sensitivity C-reactive protein: a meta-analysis of randomized controlled trials. Nutrients (2014) 6:2206-16. doi:10.3390/nu6062206.
97. Beilfuss J, Berg V, Sneve M, Jorde R, Kamycheva E. Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor necrosis factor-alpha and insulin resistance in overweight and obese subjects. Cytokine (2012) 60:870-4. doi:10.1016/j.cyto.2012.07.032.
98. Hopkins MH, Owen J, Ahearn T, Fedirko V, Flanders WD, Jones DP, et al. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer Prev Res (2011) 4:1645-54. doi:10.1158/1940-6207.capr-11-0105.
99. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr (2006) 83:754-9.
100. Yusupov E, Li-Ng M, Pollack S, Yeh JK, Mikhail M, Aloia JF. Vitamin D and serum cytokines in a randomized clinical trial. Int J Endocrinol (2010) 2010. doi:10.1155/2010/305054.
101. Shab-Bidar S, Neyestani TR, Djazayery A, Eshraghian M-R, Houshiarrad A, Kalayi A, et al. Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes. Diabetes Metab Res Rev (2012) 28:424-30. doi:10.1002/dmrr.2290.
102. Barnes MS, Horigan G, Cashman KD, Hill TR, Forsythe LK, Lucey AJ, et al. Maintenance of wintertime vitamin D status with cholecalciferol supplementation is not associated with alterations in serum cytokine concentrations among apparently healthy younger or older adults. J Nutr (2011) 141:476-81. doi:10.3945/jn.110.131516.
103. Jorde R, Sneve M, Torjesen PA, Figenschau Y, Gøransson LG, Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine (2010) 50:175-80. doi:10.1016/j.cyto.2009.12.006.
104. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care (2007) 30:980-6. doi:10.2337/dc06-1994.
105. Chandler PD, Scott JB, Drake BF, Ng K, Manson JE, Rifai N, et al. Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebo-controlled trial. Cancer Prev Res (2014) 7:218-25. doi:10.1158/1940-6207.capr-13-0338-t.
106. Carlberg C, Seuter S, de Mello VDF, Schwab U, Voutilainen S, Pulkki K, et al. Primary vitamin D target genes allow a categorization of possible benefits of vitamin D3 supplementation. PLoS One (2013) 8:e71042. doi:10.1371/journal.pone.0071042.
107. Carlberg C. Genome-wide (over)view on the actions of vitamin D. Front Physiol (2014) 5:167. doi:10.3389/fphys.2014.00167.
108. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res (2010) 20:1352-60. doi:10.1101/gr.107920.110.
109. Heikkinen S, Väisänen S, Pehkonen P, Seuter S, Benes V, Carlberg C. Nuclear hormone 1a,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res (2011) 39:9181-93. doi:10.1093/nar/gkr654.
110. Meyer MB, Goetsch PD, Pike JW. VDR/RXR and TCF4/β-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression. Mol Endocrinol (2012) 26:37-51. doi:10.1210/me.2011-1109.
111. 3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One (2013) 8:e58725. doi:10.1371/journal.pone.0058725.
112. van Etten E, Verlinden L, Giulietti A, Ramos-Lopez E, Branisteanu DD, Ferreira GB, et al. The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur J Immunol (2007) 37:395-405. doi:10.1002/eji.200636043.
113. Selvaraj P, Vidyarani M, Alagarasu K, Prabhu Anand S, Narayanan PR. Regulatory role of promoter and 3' UTR variants of vitamin D receptor gene on cytokine response in pulmonary tuberculosis. J Clin Immunol (2008) 28:306-13. doi:10.1007/s10875-007-9152-5.
114. Al-Daghri NM, Guerini FR, Al-Attas OS, Alokail MS, Alkharfy KM, Draz HM, et al. Vitamin D receptor gene polymorphisms are associated with obesity and inflammasome activity. PLoS One (2014) 9:e102141. doi:10.1371/journal.pone.0102141.
115. Aranow C. Vitamin D and the immune system. J Investig Med (2011) 59:881-6. doi:10.231/JIM.0b013e31821b8755.
116. Kongsbak M, Levring TB, Geisler C, von Essen MR. The vitamin D receptor and T cell function. Front Immunol (2013) 4:148. doi:10.3389/fimmu.2013.00148.
117. Di Rosa M, Malaguarnera G, De Gregorio C, Palumbo M, Nunnari G, Malaguarnera L. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cell Immunol (2012) 280:36-43. doi:10.1016/j.cellimm.2012.10.009.
118. Gao D, Trayhurn P, Bing C. 1,25-Dihydroxyvitamin D3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes (2013) 37:357-65. doi:10.1038/ijo.2012.53.
119. Zhang Y, Leung DYM, Richers BN, Liu Y, Remigio LK, Riches DW, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol (2012) 188:2127-35. doi:10.4049/jimmunol.1102412.
120. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 42:73-8. doi:10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G.
121. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu X-H, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology (2000) 56:671-6. doi:10.1016/S0090-4295(00)00674-9.
122. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res (2005) 65:7917-25. doi:10.1158/0008-5472.can-05-1435.
123. Bao B-Y, Yao J, Lee Y-F. 1a, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis (2006) 27:1883-93. doi:10.1093/carcin/bgl041.
124. Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res (2006) 66:4516-24. doi:10.1158/0008-5472.CAN-05-3796.
125. Giangreco AA, Nonn L. The sum of many small changes: microRNAs are specifically and potentially globally altered by vitamin D3 metabolites. J Steroid Biochem Mol Biol (2013) 136:86-93. doi:10.1016/j.jsbmb.2013.01.001.
126. Wang W-LW, Chatterjee N, Chittur SV, Welsh J, Tenniswood MP. Effects of 1a,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer (2011) 10:1-15. doi:10.1186/1476-4598-10-58.
127. Kutmon M, Coort SL, de Nooijer K, Lemmens C, Evelo C. Integrative network-based analysis of mRNA and microRNA expression in 1,25-dihydroxyvitamin D3-treated cancer cells. Genes Nutr (2015) 10:1-12. doi:10.1007/s12263-015-0484-0.
128. Singh PK, Long MD, Battaglia S, Hu Q, Liu S, Sucheston-Campbell LE, et al. VDR regulation of microRNA differs across prostate cell models suggesting extremely flexible control of transcription. Epigenetics (2015) 10:40-9. doi:10.4161/15592294.2014.989088.
129. Giangreco AA, Vaishnav A, Wagner D, Finelli A, Fleshner N, Van der Kwast T, et al. Tumor suppressor microRNAs, miR-100 and-125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev Res (2013) 6:483-94. doi:10.1158/1940-6207.capr-12-0253.
130. Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab (2013) 98:1498-507. doi:10.1210/jc.2012-4019.
131. Schetter AJ, Heegaard NHH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2010) 31:37-49. doi:10.1093/carcin/bgp272.
132. Chandler PD, Giovannucci EL, Scott JB, Bennett GG, Ng K, Chan AT, et al. Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial. Cancer Epidemiol Biomarkers Prev (2014) 23:1944-7. doi:10.1158/1055-9965.epi-14-0522.
133. D'Amico AV, Renshaw AA, Sussman B, Chen M. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA (2005) 294:440-7. doi:10.1001/jama.294.4.440.
134. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol (1998) 159:2035-40. doi:10.1016/S0022-5347(01)63236-1.
135. Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer (2003) 97:1217-24. doi:10.1002/cncr.11179.
136. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab (2012) 97:2315-24. doi:10.1210/jc.2012-1451.
137. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet (2011) 7:e1001387. doi:10.1371/journal.pgen.1001387.
138. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 43:570-3. doi:10.1038/ng.839.
139. Bock C, Schwartz A, Ruterbusch J, Levin A, Neslund-Dudas C, Land S, et al. Results from a prostate cancer admixture mapping study in African-American men. Hum Genet (2009) 126:637-42. doi:10.1007/s00439-009-0712-z.
140. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 103:14068-73. doi:10.1073/pnas.0605832103.
141. Han Y, Signorello LB, Strom SS, Kittles RA, Rybicki BA, Stanford JL, et al. Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer (2014) 136:1210-7. doi:10.1002/ijc.29066.
142. Fetahu IS, Höbaus J, Kallay E. Vitamin D and the epigenome. Front Physiol (2014) 5:164. doi:10.3389/fphys.2014.00164.
143. Rawson JB, Sun Z, Dicks E, Daftary D, Parfrey PS, Green RC, et al. Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients. Nutr Cancer (2012) 64:919-28. doi:10.1080/01635581.2012.711418.
144. Doig CL, Singh PK, Dhiman VK, Thorne JL, Battaglia S, Sobolewski M, et al. Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns. Carcinogenesis (2013) 34:248-56. doi:10.1093/carcin/bgs331.
145. Campbell MJ. Vitamin D and the RNA transcriptome: more than mRNA regulation. Front Physiol (2014) 5:181. doi:10.3389/fphys.2014.00181.